News
NPCE
7.56
-37.10%
-4.46
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 16h ago
NeuroPace Falls on Lowered Full-Year Guidance Amid Account Issues
Dow Jones · 16h ago
NeuroPace Price Target Cut to $9.00/Share From $20.00 by JP Morgan
Dow Jones · 18h ago
NeuroPace Cut to Neutral From Overweight by JP Morgan
Dow Jones · 18h ago
Leerink downgrades NeuroPace amid commercial setbacks, cuts to growth outlook
TipRanks · 19h ago
NeuroPace Is Maintained at Overweight by Keybanc
Dow Jones · 19h ago
NeuroPace Price Target Cut to $14.00/Share From $18.00 by Keybanc
Dow Jones · 19h ago
NeuroPace price target lowered to $13 from $20 at Lake Street
TipRanks · 19h ago
Keybanc Maintains Overweight on NeuroPace, Lowers Price Target to $14
Benzinga · 19h ago
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
TipRanks · 20h ago
NeuroPace price target lowered to $14 from $18 at KeyBanc
TipRanks · 20h ago
NeuroPace Price Target Announced at $7.00/Share by Leerink Partners
Dow Jones · 20h ago
NeuroPace Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 20h ago
Leerink Partners Downgrades NeuroPace to Market Perform, Announces $7 Price Target
Benzinga · 20h ago
NeuroPace downgraded to Neutral from Overweight at JPMorgan
TipRanks · 21h ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 21h ago
NeuroPace downgraded to Market Perform from Outperform at Leerink
TipRanks · 21h ago
NeuroPace Shares Plunge 33.61% After-Hours: Here's What Investors Should Know
Benzinga · 1d ago
NeuroPace (NPCE) Q3 2026 Earnings Call Transcript
NASDAQ · 1d ago
Closing Bell Movers: Cerebras jumps 18% after Q3 earnings beat
TipRanks · 1d ago
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.